Press release
Primary Biliary Cholangitis Market Outlook 2034: Growth Momentum Strengthens with Emerging Pipeline Innovations | DelveInsight
Primary Biliary Cholangitis Market
Get a complimentary sample of the Primary Biliary Cholangitis Market Size, Share & Forecast Report:
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Primary Biliary Cholangitis Market Report
• The Primary Biliary Cholangitis market was valued at nearly USD 1.15 billion in 2023 and is expected to expand at a noteworthy CAGR throughout the forecast timeline (2020-2034).
• In March 2026, GSK finalized a late-stage agreement granting Alfasigma commercialization rights for linerixibat, an IBAT inhibitor currently under regulatory review globally for treating cholestatic pruritus in PBC. The deal includes an upfront payment of $300 million, with additional milestone-based payments tied to regulatory approvals and sales performance.
• In September 2025, Zydus Therapeutics announced plans to file for US FDA approval of saroglitazar magnesium following strong Phase IIb/III EPICS-III trial outcomes, particularly in patients unresponsive to ursodeoxycholic acid (UDCA).
• In the same month, Intercept Pharmaceuticals withdrew Ocaliva (obeticholic acid) from the US market after FDA concerns regarding serious liver injury risks, alongside halting ongoing clinical trials.
• Zydus Therapeutics further reported that saroglitazar achieved a 48.5% improvement in biochemical response versus placebo, marked by reductions in alkaline phosphatase levels-an important marker of disease progression.
• In May 2025, Dr. Falk Pharma's norucholic acid demonstrated statistically significant improvements in a Phase III trial for PSC, including reductions in alkaline phosphatase levels and slowing disease progression.
• Galmed Pharmaceuticals also reported promising preclinical findings for Aramchol, highlighting its anti-fibrotic potential and ability to modulate key signaling pathways in cholangiopathies.
• Chemomab Therapeutics shared positive results from the extension phase of its SPRING trial for nebokitug, showing continued patient participation and extended treatment benefits.
• COUR Pharmaceuticals received FDA Orphan Drug Designation in January 2025 for CNP-104, targeting immune-mediated pathways in PBC.
• Gilead Sciences received a positive CHMP opinion for seladelpar in December 2024, with final European Commission approval anticipated shortly thereafter.
• Interim Phase III data from the ASSURE study showed strong biochemical response rates with seladelpar, including normalization of ALP levels in a significant proportion of patients.
• Ipsen secured conditional EU approval for elafibranor (Iqirvo®), a dual PPARα/δ agonist targeting bile acid regulation, inflammation, and fibrosis.
• The FDA granted accelerated approval to seladelpar in August 2024 for use in PBC patients with inadequate response or intolerance to UDCA.
• The United States accounted for the largest diagnosed patient population in 2023, with numbers expected to rise steadily through 2034.
• Among European countries, Germany reported the highest diagnosed prevalence, exceeding 34,000 cases in 2023.
• Age-wise analysis indicates peak prevalence between 40-70 years, with a significant rise in cases as age increases.
• Gender-based analysis shows a strong female predominance, accounting for approximately 82% of cases in the US.
• Leading companies operating in the PBC space include CymaBay Therapeutics, Zydus Therapeutics, Gannex Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Novartis, Merck & Co., Mirum Pharmaceuticals, Genfit, Calliditas Therapeutics, and others.
• Key therapies in development and commercialization include seladelpar, saroglitazar, ASC42, obeticholic acid, bezafibrate, elafibranor, volixibat, setanaxib, and multiple pipeline candidates.
• The PBC market is projected to grow significantly due to increasing disease awareness, improved diagnosis rates, and the launch of innovative therapies that are expected to transform treatment paradigms.
Primary Biliary Cholangitis Overview
Primary Biliary Cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is a chronic autoimmune disorder affecting the small bile ducts in the liver. Progressive inflammation and damage lead to bile accumulation, resulting in liver injury and eventual fibrosis or cirrhosis.
Explore detailed insights on market trends, drug uptake, and treatment outlook:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Epidemiology Insights
The epidemiology section of the report evaluates past, present, and future disease trends across the 7MM from 2020 to 2034. It provides a comprehensive understanding of patient distribution, growth patterns, and key contributing factors through extensive research and expert opinions.
Segmentation includes:
• Total prevalence
• Severity-based prevalence
• Gender-specific distribution
• Diagnosed patient population
Download the epidemiology forecast report: https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Drug Uptake and Pipeline Landscape
The report assesses adoption trends of newly launched and upcoming therapies, analyzing their market penetration, patient uptake, and commercial performance. It also highlights leading pipeline candidates, ongoing clinical developments, and strategic collaborations shaping the competitive landscape.
Key Therapies and Companies
Prominent therapies include seladelpar, saroglitazar, ASC42, obeticholic acid, bezafibrate, CNP-104, volixibat, elafibranor, setanaxib, and others, developed by major players such as CymaBay Therapeutics, Zydus Therapeutics, Novartis, Merck & Co., Mirum Pharmaceuticals, and more.
Discover upcoming therapies expected to capture significant market share:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Market Drivers
• Growing awareness and early diagnosis
• Increasing prevalence, particularly among women
• Advancements beyond UDCA therapy
• Strong late-stage pipeline and innovation
Market Challenges
• High cost of advanced treatments
• Limited patient population due to rare disease nature
• Safety concerns associated with certain therapies
• Delayed diagnosis in early stages
• Regulatory complexities in clinical development
Scope of the Primary Biliary Cholangitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Primary Biliary Cholangitis Companies: CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others
• Key Primary Biliary Cholangitis Therapies: Seladelpar, Saroglitazar, ASC42, Obeticholic, Bezafibrate, EDP-305, CNP-104, LJN452, Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Volixibat, Elafibranor, MBX-8025, Setanaxib, HTD1801 (BUDCA), A3907, HK-660S, Cenicriviroc, PLN-74809, BTT1023, and others
• Primary Biliary Cholangitis Therapeutic Assessment: Primary Biliary Cholangitis current marketed and Primary Biliary Cholangitis emerging therapies
• Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis market drivers and Primary Biliary Cholangitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Primary Biliary Cholangitis Unmet Needs, KOL's views, Analyst's views, Primary Biliary Cholangitis Market Access and Reimbursement
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Market Outlook 2034: Growth Momentum Strengthens with Emerging Pipeline Innovations | DelveInsight here
News-ID: 4457116 • Views: …
More Releases from DelveInsight Business Research
Lewy Body Dementia Market Set for Robust Growth Driven by Innovation and Pipelin …
DelveInsight's "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market…
Celiac Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial P …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 30+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Celiac Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.
The Celiac…
Hemophilia B Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Upda …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hemophilia B Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B Market.
The Hemophilia B Pipeline…
Spinal Cord Injury Market Poised for Sustained Growth Amid Advancements in Treat …
DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the key facts of the…
More Releases for Primary
Premier Primary Care Medicine Recognized as a Top Primary Care Doctor in Smyrna, …
Premier Primary Care Medicine has been recognized as one of the Top Primary Care Doctors in Smyrna, GA, a distinction that underscores the practice's dedication to delivering high-quality, patient-focused healthcare to the local community. This recognition affirms the practice's strong reputation for clinical expertise, compassionate service, and commitment to improving long-term health outcomes for patients across Smyrna and surrounding areas.
SMYRNA, GA - March 3, 2026 - Premier Primary Care [https://www.premierpcmed.com/]…
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
